Advanced Filters
noise

Kogarah, Australia Clinical Trials

A listing of Kogarah, Australia clinical trials actively recruiting patients volunteers.

Found 313 clinical trials

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or …

18 years of age All Phase 1/2
L Lisa Turner

Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System

To evaluate the safety and effectiveness of the BlueLeaf System for the restoration of venous competence for the treatment of symptomatic chronic venous insufficiency (CVI).

18 years of age All Phase N/A
A Annette Guy

Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy

This is an open-label phase 2/3 study for individuals with Congenital Myotonic Dystrophy (Congenital DM1) who participated in the preceding AMO-02-MD-2-003 study or individuals with either Congenital or Childhood Onset DM1 who are treatment naïve.

6 - 45 years of age All Phase 2/3
J Jasmine Boudreau

A Comparison of JointRep® and Microfracture in Repair of Cartilage Lesions on the Femoral Condyle or Trochlea,

The aim of the study is to compare whether JointRep® plus microfracture is more effective than microfracture alone when treating symptomatic focal articular cartilage lesions in the knee (femoral condyles or trochlea).

18 - 65 years of age All Phase N/A
P Paul DeSouza

Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients

This study aims to find out: The tolerability of Cabotamig (ARB202) in adults with advanced solid gastrointestinal tumors who failed the standard treatment. People can participate if their tumor has the CDH17 marker. To find out how study drug is broken down in the body To know the effects of …

18 years of age All Phase 1
K Kathleen Dorris, MD

MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. The biological activity of binimetinib that has been evaluated bith in vitro and in vivo in a wide variety of tumor types In this Phase II, the drug will be used …

1 - 25 years of age All Phase 2

Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

This is a Phase 1 open-label, non-randomized, multi-center clinical trial of intratumoral IVX037 in people with micro satellite-stable (MSS) colorectal or gastroesophageal cancer metastatic to liver, or advanced ovarian cancer.

18 - 85 years of age All Phase 1
D Douglas Orr, MD

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug CS5001 in patients with advanced hematological and solid tumors.

18 years of age All Phase 1

Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS

The goal of this project is to see if two new potential treatments (defactinib and the combination tablet of decitabine/cedazuridine) can safely be combined to improve outcomes in people with high-risk myelodysplastic syndrome (MDS), certain forms of Acute Myeloid Leukaemia (AML), and Chronic Myelomonocytic Leukaemia (CMML). Decitabine/cedazuridine is approved for …

18 years of age All Phase 1

Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction

The study's purpose is to understand the appearance of your prostate-specific membrane antigen (PSMA) PET scan after you take 14 days of treatment with a drug called dasatinib alone or in combination with anti-testosterone drug call darolutamide. Who is it for? You may be eligible to join this study if …

18 years of age Male Phase 2

Simplify language using AI